https://doi.org/10.4081/monaldi.2021.1617
Single inhaler triple therapy in COPD – all that glitters is not gold
Submitted: September 22, 2020
Accepted: November 30, 2020
Published: April 28, 2021
Accepted: November 30, 2020
Abstract Views: 1174
PDF: 634
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Dear Editor,
The recent studies on combination triple therapy of inhaled corticosteroid, long acting beta2 agonist and long-acting muscarinic antagonist (ICS-LABA-LAMA) in COPD have consistently demonstrated an improvement in exacerbation frequency and/or improvement of lung function...
Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with Fluticasone furoate/Umeclidinium/Vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020;201:1508-16.
DOI: https://doi.org/10.1164/rccm.201911-2207OC
Casas A, Montes de Oca M, Menezes AM, et al. Respiratory medication used in COPD patients from seven latin american countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis 2018;13:1545-56.
DOI: https://doi.org/10.2147/COPD.S154097
Buhl R, Criée C-P, Kardos P, et al. Patients in clinical trials on COPD triple therapy compared to real world populations Am J Respir Crit Care Med 2019;199:A1117.
DOI: https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1117
Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390-8.
DOI: https://doi.org/10.1016/S2213-2600(16)00100-4
Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004;126:59-65.
DOI: https://doi.org/10.1378/chest.126.1.59
Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018;6:747-8.
DOI: https://doi.org/10.1016/S2213-2600(18)30327-8
Palli SR, Frazer M, DuCharme M, et al. Differences in real-world health and economic outcomes among patients with COPD treated with combination tiotropium/olodaterol versus triple therapy. J Manag Care Spec Pharm 2020;26:1363-74.
DOI: https://doi.org/10.18553/jmcp.2020.20159
Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020;383:35-48.
DOI: https://doi.org/10.1056/NEJMoa1916046
How to Cite
Deshmukh, Kartik, and Arjun Khanna. 2021. “Single Inhaler Triple Therapy in COPD – All That Glitters Is Not Gold”. Monaldi Archives for Chest Disease 91 (2). https://doi.org/10.4081/monaldi.2021.1617.
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- T. Kinnunen, O. Säynäjäkangas, T. Keistinen, Features of hospitalisations for acute exacerbation of COPD resulting in death , Monaldi Archives for Chest Disease: Vol. 67 No. 1 (2007): Pulmonary series
- S.M. Tariq, J. George, S. Srinivasan, Inhaled foreign bodies in adolescents and adults , Monaldi Archives for Chest Disease: Vol. 63 No. 4 (2005): Pulmonary series
- R. Luzzati, M. Confalonieri, A. Cazzadori, P. Della Loggia, R. Cifaldi, C. Fabris, M. Biolo, M. Borelli, C. Longo, E. Concia, Prolonged hospitalisation for immigrants and high risk patients with positive smear pulmonary tuberculosis , Monaldi Archives for Chest Disease: Vol. 75 No. 2 (2011): Pulmonary series
- Y. Lacasse, L. Beaudoin, L. Rousseau, F. Maltais, Randomized trial of paroxetine in end-stage COPD , Monaldi Archives for Chest Disease: Vol. 61 No. 3 (2004): Pulmonary series
- I. Chkhaidze, T. Maglakelidze, N. Khaltaev, Chronic respiratory diseases at primary health care level in Georgia: the results of the pilot study , Monaldi Archives for Chest Disease: Vol. 71 No. 4 (2009): Pulmonary series
- M. Lusuardi, G. Garuti, M. Massobrio, L. Spagnolatti, S. Bendinelli, Heart and Lungs in COPD. Close friends in real life - separate in daily medical practice? , Monaldi Archives for Chest Disease: Vol. 69 No. 1 (2008): Pulmonary series
- Alfredo Monteverde, Valeria Carlino, Giulia Ganci, Giuseppe Taormina, Mario Barbagallo, Treatment of heart failure with preserved ejection fraction , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
- Bruno Balbi, Claudio Marcassa, Fabrizio Pisani, Giacomo Corica, Antonio Spanevello, Integrated care of chronic degenerative non-communicable diseases and rehabilitation: the odd couple? , Monaldi Archives for Chest Disease: Vol. 87 No. 1 (2017)
- Chiara Francesca Carraro, Two cases of COPD benefitting from therapy with roflumilast , Monaldi Archives for Chest Disease: Vol. 79 No. 3-4 (2013): Pulmonary series - Supplement 1
- A. Yilmaz, G. Bektemur, G.H. Ekinci, E.A. Ongel, M. Kavas, O. Haciomeroglu, M. Demir, B. Burunsuzoglu, Extralobar pulmonary sequestration: a case report , Monaldi Archives for Chest Disease: Vol. 79 No. 2 (2013): Pulmonary series
<< < 2 3 4 5 6 7 8 9 10 11 > >>
You may also start an advanced similarity search for this article.
